Predictors for Clinical Benefit of Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis

References

• Siegel RL , MillerKD , JemalA . Cancer Statistics, 2017 . CA Cancer J. Clin.67 ( 1 ), 7 – 30 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Pardoll DM . The blockade of immune checkpoints in cancer immunotherapy . Nat. Rev. Cancer12 ( 4 ), 252 – 264 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Herbst RS , BaasP , KimDWet al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial . Lancet387 ( 10027 ), 1540 – 1550 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Borghaei H , Paz-AresL , HornLet al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer . N. Engl. J. Med.373 ( 17 ), 1627 – 1639 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Brahmer J , ReckampKL , BaasPet al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer . N. Engl. J. Med.373 ( 2 ), 123 – 135 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Fehrenbacher L , SpiraA , BallingerMet al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial . Lancet387 ( 10030 ), 1837 – 1846 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Rittmeyer A , BarlesiF , WaterkampDet al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial . Lancet389 ( 10066 ), 255 – 265 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Barlesi F , VansteenkisteJ , SpigelDet al. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study . Lancet Oncol. ( 2018 ) ( Epub ahead of print ).
   PubMed Web of Science ®Google Scholar
• Reck M , Rodriguez-AbreuD , RobinsonAGet al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer . N. Engl. J. Med.375 ( 19 ), 1823 – 1833 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Forde PM , ChaftJE , PardollDM . Neoadjuvant PD-1 blockade in resectable lung cancer . N. Engl. J. Med.379 ( 9 ), e14 ( 2018 ).
   PubMedGoogle Scholar
• Goodman AM , KatoS , BazhenovaLet al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers . Mol. Cancer Ther.16 ( 11 ), 2598 – 2608 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Wu Y , JuQ , QianB , ZhangF , ShiH . The effectiveness of PD-1 inhibitors in non-small cell lung cancer (NSCLC) patients of different ages . Oncotarget9 ( 8 ), 7942 – 7948 ( 2018 ).
   PubMedGoogle Scholar
• Jiang Q , XieM , HeM , YanF , ZhangX , YuS . Anti-PD-1/PD-L1 antibodies versus docetaxel in patients with previously treated non-small-cell lung cancer . Oncotarget9 ( 7 ), 7672 – 7683 ( 2018 ).
   PubMedGoogle Scholar
• Conforti F , PalaL , BagnardiVet al. Cancer immunotherapy efficacy and patients’ sex: a systematic review and meta-analysis . Lancet Oncol.19 ( 6 ), 737 – 746 ( 2018 ).
   PubMed Web of Science ®Google Scholar
• Pinto JA , VallejosCS , RaezLEet al. Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy? ESMO Open 3 ( 3 ), e000344 ( 2018 ).
   PubMed Web of Science ®Google Scholar
• Rizvi NA , HellmannMD , SnyderAet al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer . Science348 ( 6230 ), 124 – 128 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Lee CK , ManJ , LordSet al. Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer-a meta-analysis . J. Thorac. Oncol.12 ( 2 ), 403 – 407 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• El-Osta H , ShahidK , MillsGM , PeddiP . Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment . Onco. Targets Ther.9 , 5101 – 5116 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Dwary AD , MasterS , PatelAet al. Excellent response to chemotherapy post immunotherapy . Oncotarget8 ( 53 ), 91795 – 91802 ( 2017 ).
   PubMedGoogle Scholar
• Schvartsman G , PengSA , BisGet al. Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer . Lung Cancer112 , 90 – 95 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Kim J , ChoJ , LeeMH , LimJH . Relative efficacy of checkpoint inhibitors for advanced NSCLC according to programmed death-ligand-1 expression: a systematic review and network meta-analysis . Sci Rep.8 ( 1 ), 11738 ( 2018 ).
   PubMedGoogle Scholar
• Goldberg SB , GettingerSN , MahajanAet al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial . Lancet Oncol.17 ( 7 ), 976 – 983 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Lukas RV , GandhiM , O’hearCet al. Safety and efficacy analyses of atezolizumab in advanced non-small-cell lung cancer (NSCLC) patients with or without baseline brain metastases . Ann. Oncol.28 ( suppl_2 ), ii28 – ii51 ( 2017 ).
   Google Scholar
• Chen L , DouglassJ , KleinbergLet al. Concurrent immune checkpoint inhibitors and stereotactic radiosurgery for brain metastases in non-small cell lung cancer, melanoma, and renal cell carcinoma . Int. J. Radiat. Oncol. Biol. Phys.100 ( 4 ), 916 – 925 ( 2018 ).
   PubMed Web of Science ®Google Scholar
• Gandhi L , Rodriguez-AbreuD , GadgeelSet al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer . N. Engl. J. Med.378 ( 22 ), 2078 – 2092 ( 2018 ).
   PubMed Web of Science ®Google Scholar
• Antonia SJ , VillegasA , DanielDet al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer . N. Engl. J. Med.377 ( 20 ), 1919 – 1929 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Antonia SJ , VillegasA , DanielDet al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC . N. Engl. J. Med. ( 2018 ) ( Epub ahead of print ).
   Web of Science ®Google Scholar
• Carbone DP , ReckM , Paz-AresLet al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer . N. Engl. J. Med.376 ( 25 ), 2415 – 2426 ( 2017 ).
   PubMed Web of Science ®Google Scholar